BIOMAT Database Logo BIOMAT Database Logo

Long-term maraviroc use as salvage therapy in HIV-2 infection. 2012

Umbelina Caixas, and Joana Ferreira, and Aline T Marinho, and Inês Faustino, and Nádia M Grilo, and Fátima Lampreia, and Isabel Germano, and Emília C Monteiro, and Sofia A Pereira

UI MeSH Term Description Entries
D003510 Cyclohexanes Six-carbon alicyclic hydrocarbons.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077592 Maraviroc A cyclohexane and triazole derivative that acts as an antagonist of the CCR5 RECEPTOR. It prevents infection by HIV-1 virus strains which use CCR5 as a co-receptor for membrane fusion and cellular entry. 4,4-Difluoro-N-((1S)-3-(exo-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo(3.2.1)oct-8-yl)-1-phenylpropyl)cyclohexanecarboxamide,Selzentry,UK-427,857,UK-427857,UK 427,857,UK 427857,UK427,857,UK427857
D014230 Triazoles Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3. Triazole
D015498 HIV-2 An HIV species related to HIV-1 but carrying different antigenic components and with differing nucleic acid composition. It shares serologic reactivity and sequence homology with the simian Lentivirus SIMIAN IMMUNODEFICIENCY VIRUS and infects only T4-lymphocytes expressing the CD4 phenotypic marker. HTLV-IV,Human T-Lymphotropic Virus Type IV,Human immunodeficiency virus 2,LAV-2,HIV-II,Human Immunodeficiency Virus Type 2,Human T Lymphotropic Virus Type IV,Immunodeficiency Virus Type 2, Human,SBL-6669
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D016879 Salvage Therapy A therapeutic approach, involving chemotherapy, radiation therapy, or surgery, after initial regimens have failed to lead to improvement in a patient's condition. Salvage therapy is most often used for neoplastic diseases. Salvage Treatment,Therapy, Salvage,Salvage Therapies,Salvage Treatments,Therapies, Salvage,Treatment, Salvage,Treatments, Salvage
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D016903 Drug Monitoring The process of observing, recording, or detecting the effects of a chemical substance administered to an individual therapeutically or diagnostically. Monitoring, Drug,Therapeutic Drug Monitoring,Drug Monitoring, Therapeutic,Monitoring, Therapeutic Drug
D018791 CD4 Lymphocyte Count The number of CD4-POSITIVE T-LYMPHOCYTES per unit volume of BLOOD. Determination requires the use of a fluorescence-activated flow cytometer. Lymphocyte Count, CD4,T4 Lymphocyte Count,CD4 Cell Counts,CD4 Counts,CD4+ Cell Counts,CD4+ Counts,CD4 Cell Count,CD4 Count,CD4 Lymphocyte Counts,CD4+ Cell Count,CD4+ Count,Count, T4 Lymphocyte,Counts, T4 Lymphocyte,Lymphocyte Count, T4,Lymphocyte Counts, CD4,Lymphocyte Counts, T4,T4 Lymphocyte Counts

Related Publications

Umbelina Caixas, and Joana Ferreira, and Aline T Marinho, and Inês Faustino, and Nádia M Grilo, and Fátima Lampreia, and Isabel Germano, and Emília C Monteiro, and Sofia A Pereira
[Salvage therapy in HIV infection].
April 2004, MMW Fortschritte der Medizin,
Umbelina Caixas, and Joana Ferreira, and Aline T Marinho, and Inês Faustino, and Nádia M Grilo, and Fátima Lampreia, and Isabel Germano, and Emília C Monteiro, and Sofia A Pereira
[Salvage therapy for HIV infection].
April 2005, MMW Fortschritte der Medizin,
Umbelina Caixas, and Joana Ferreira, and Aline T Marinho, and Inês Faustino, and Nádia M Grilo, and Fátima Lampreia, and Isabel Germano, and Emília C Monteiro, and Sofia A Pereira
Zidovudine as modern day salvage therapy for HIV infection.
November 2014, AIDS patient care and STDs,
Umbelina Caixas, and Joana Ferreira, and Aline T Marinho, and Inês Faustino, and Nádia M Grilo, and Fátima Lampreia, and Isabel Germano, and Emília C Monteiro, and Sofia A Pereira
Salvage antiretroviral therapy in HIV infection.
February 2002, Expert opinion on pharmacotherapy,
Umbelina Caixas, and Joana Ferreira, and Aline T Marinho, and Inês Faustino, and Nádia M Grilo, and Fátima Lampreia, and Isabel Germano, and Emília C Monteiro, and Sofia A Pereira
Maraviroc first-line therapy for HIV infection. Too risky.
November 2010, Prescrire international,
Umbelina Caixas, and Joana Ferreira, and Aline T Marinho, and Inês Faustino, and Nádia M Grilo, and Fátima Lampreia, and Isabel Germano, and Emília C Monteiro, and Sofia A Pereira
Maraviroc: a review of its use in HIV infection and beyond.
January 2015, Drug design, development and therapy,
Umbelina Caixas, and Joana Ferreira, and Aline T Marinho, and Inês Faustino, and Nádia M Grilo, and Fátima Lampreia, and Isabel Germano, and Emília C Monteiro, and Sofia A Pereira
Optimizing care for patients on maraviroc salvage therapy.
January 2009, HIV clinician,
Umbelina Caixas, and Joana Ferreira, and Aline T Marinho, and Inês Faustino, and Nádia M Grilo, and Fátima Lampreia, and Isabel Germano, and Emília C Monteiro, and Sofia A Pereira
Maraviroc in the treatment of HIV infection.
February 2009, Drug design, development and therapy,
Umbelina Caixas, and Joana Ferreira, and Aline T Marinho, and Inês Faustino, and Nádia M Grilo, and Fátima Lampreia, and Isabel Germano, and Emília C Monteiro, and Sofia A Pereira
Clinical outcome in resistant HIV-2 infection treated with raltegravir and maraviroc.
May 2010, Antiviral research,
Umbelina Caixas, and Joana Ferreira, and Aline T Marinho, and Inês Faustino, and Nádia M Grilo, and Fátima Lampreia, and Isabel Germano, and Emília C Monteiro, and Sofia A Pereira
Long-term intrapatient viral evolution during HIV-2 infection.
March 2007, The Journal of infectious diseases,
Copied contents to your clipboard!